CN1187094C - 多元醇干扰素β偶联物 - Google Patents

多元醇干扰素β偶联物 Download PDF

Info

Publication number
CN1187094C
CN1187094C CNB998054968A CN99805496A CN1187094C CN 1187094 C CN1187094 C CN 1187094C CN B998054968 A CNB998054968 A CN B998054968A CN 99805496 A CN99805496 A CN 99805496A CN 1187094 C CN1187094 C CN 1187094C
Authority
CN
China
Prior art keywords
peg
ifn
polyol
interferon
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998054968A
Other languages
English (en)
Chinese (zh)
Other versions
CN1302209A (zh
Inventor
N·埃尔塔亚
M·J·罗伯茨
M·哈里斯
W·索利维切
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of CN1302209A publication Critical patent/CN1302209A/zh
Application granted granted Critical
Publication of CN1187094C publication Critical patent/CN1187094C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB998054968A 1998-04-28 1999-04-28 多元醇干扰素β偶联物 Expired - Fee Related CN1187094C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
US60/083,339 1998-04-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100898478A Division CN100335503C (zh) 1998-04-28 1999-04-28 多元醇干扰素β偶联物

Publications (2)

Publication Number Publication Date
CN1302209A CN1302209A (zh) 2001-07-04
CN1187094C true CN1187094C (zh) 2005-02-02

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998054968A Expired - Fee Related CN1187094C (zh) 1998-04-28 1999-04-28 多元醇干扰素β偶联物
CNB2004100898478A Expired - Fee Related CN100335503C (zh) 1998-04-28 1999-04-28 多元醇干扰素β偶联物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2004100898478A Expired - Fee Related CN100335503C (zh) 1998-04-28 1999-04-28 多元醇干扰素β偶联物

Country Status (30)

Country Link
US (3) US6638500B1 (enExample)
EP (2) EP1421956B1 (enExample)
JP (2) JP4574007B2 (enExample)
KR (1) KR100622796B1 (enExample)
CN (2) CN1187094C (enExample)
AR (1) AR020070A1 (enExample)
AT (2) ATE365563T1 (enExample)
AU (1) AU762621B2 (enExample)
BG (2) BG64694B1 (enExample)
BR (1) BR9910023A (enExample)
CA (2) CA2330451A1 (enExample)
CY (1) CY1108022T1 (enExample)
CZ (2) CZ298579B6 (enExample)
DE (2) DE69936409T2 (enExample)
DK (2) DK1075281T3 (enExample)
EA (2) EA003789B1 (enExample)
EE (1) EE05214B1 (enExample)
ES (2) ES2285286T3 (enExample)
HU (1) HUP0300548A3 (enExample)
IL (1) IL139286A (enExample)
NO (2) NO329749B1 (enExample)
NZ (1) NZ507456A (enExample)
PL (2) PL193352B1 (enExample)
PT (2) PT1421956E (enExample)
SI (2) SI1075281T1 (enExample)
SK (2) SK286654B6 (enExample)
TR (2) TR200101751T2 (enExample)
TW (2) TWI266800B (enExample)
UA (2) UA66857C2 (enExample)
WO (1) WO1999055377A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
AU766190B2 (en) 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
HUP0201425A3 (en) * 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
TR200101086A3 (enExample) * 1999-10-15 2001-08-21
US7691367B2 (en) 1999-12-24 2010-04-06 Kyowa Hakko Kirin Co., Ltd. Branched polyalkylene glycols
HUP0203751A3 (en) 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
CA2436623C (en) * 2001-01-30 2011-08-02 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
EP1366075B1 (en) 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
KR100961859B1 (ko) 2001-07-11 2010-06-09 맥시겐 홀딩스 엘티디 지-씨에스에프 접합체
PT3025726T (pt) 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050501A (sr) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora
GEP20084486B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
EP2085470B1 (en) 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
US7879320B2 (en) 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
US7731948B2 (en) 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
EA012281B1 (ru) 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
JP5243041B2 (ja) * 2004-12-21 2013-07-24 ネクター セラピューティックス 安定化ポリマーチオール試薬
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
BRPI0614257A2 (pt) * 2005-08-04 2011-03-15 Nektar Therapeutics Al Corp conjugados de uma porção de g-csf e um polìmero
US20080219952A1 (en) 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
EP1933860A2 (en) 2005-09-01 2008-06-25 Ares Trading S.A. Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
CA2653748A1 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
AU2007253264A1 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Factor IX analogues having prolonged in vivo half life
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
RS52417B (sr) 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
JP2013532176A (ja) 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
IN2014CN02982A (enExample) * 2011-10-01 2015-07-03 Glytech Inc
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US20150030564A1 (en) 2012-02-29 2015-01-29 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
AU2014245917B2 (en) 2013-03-29 2017-09-28 Glytech, Inc. Polypeptide having sialylated sugar chains attached thereto
US11759500B2 (en) 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
SI3183264T1 (sl) 2014-08-19 2021-03-31 Biogen Ma Inc. Metoda pegilacije
ES2903448T3 (es) 2015-05-01 2022-04-01 Allysta Pharmaceuticals Inc Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
EP3795591B1 (en) * 2015-06-19 2023-09-27 Eisai R&D Management Co., Ltd. Cys80 conjugated immunoglobulins
DK3998067T3 (da) 2015-11-09 2024-10-28 Univ Colorado Regents Sammensætninger og fremgangsmåder til behandling af homocystinuri
CA3059592A1 (en) * 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
CN113382775A (zh) 2019-01-28 2021-09-10 东丽株式会社 肝细胞生长因子或其活性片段的聚乙二醇修饰物
EP3919128A4 (en) 2019-01-28 2023-01-11 Toray Industries, Inc. POLYETHYLENE GLYCOL MODIFIED BODY FOR HEPATORYTE GROWTH FACTOR OR ACTIVE FRAGMENT THEREOF
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
EE9600121A (et) 1994-03-31 1997-04-15 Amgen Inc. Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
EA005495B1 (ru) 2005-02-24
UA79430C2 (en) 2007-06-25
TR200003161T2 (tr) 2001-01-22
UA66857C2 (uk) 2004-06-15
BG109291A (en) 2006-04-28
AU762621B2 (en) 2003-07-03
ATE365563T1 (de) 2007-07-15
NO20005337L (no) 2000-12-28
NO20005337D0 (no) 2000-10-23
HUP0300548A3 (en) 2005-07-28
IL139286A0 (en) 2001-11-25
CZ20003995A3 (en) 2001-06-13
JP2010184929A (ja) 2010-08-26
CZ298579B6 (cs) 2007-11-14
BG65046B1 (bg) 2007-01-31
HK1076115A1 (zh) 2006-01-06
JP2002512983A (ja) 2002-05-08
PL193352B1 (pl) 2007-02-28
CA2565375A1 (en) 1999-11-04
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
EP1421956B1 (en) 2007-06-27
DE69936409D1 (de) 2007-08-09
BG64694B1 (bg) 2005-12-30
DK1075281T3 (da) 2005-01-03
HUP0300548A2 (hu) 2003-06-28
US20070141620A1 (en) 2007-06-21
SK286654B6 (sk) 2009-03-05
EA200300382A1 (ru) 2005-02-24
ATE275422T1 (de) 2004-09-15
US6638500B1 (en) 2003-10-28
BR9910023A (pt) 2000-12-26
SK286217B6 (sk) 2008-05-06
NO20100324L (no) 2000-12-28
NO329749B1 (no) 2010-12-13
CN100335503C (zh) 2007-09-05
DK1421956T3 (da) 2007-10-01
AR020070A1 (es) 2002-04-10
PT1421956E (pt) 2007-07-13
HK1038194A1 (zh) 2002-03-08
BG104871A (bg) 2001-07-31
CZ298597B6 (cs) 2007-11-21
TWI232882B (en) 2005-05-21
NZ507456A (en) 2003-10-31
TR200101751T2 (tr) 2002-05-21
ES2224649T3 (es) 2005-03-01
TWI266800B (en) 2006-11-21
EA200001111A1 (ru) 2001-04-23
ES2285286T3 (es) 2007-11-16
DE69920002D1 (de) 2004-10-14
EE200000614A (et) 2002-04-15
KR100622796B1 (ko) 2006-09-13
SK16222000A3 (sk) 2001-04-09
WO1999055377A2 (en) 1999-11-04
IL139286A (en) 2005-12-18
US7357925B2 (en) 2008-04-15
WO1999055377A3 (en) 1999-12-29
PT1075281E (pt) 2004-11-30
CN1302209A (zh) 2001-07-04
AU3767499A (en) 1999-11-16
EA003789B1 (ru) 2003-10-30
SI1075281T1 (en) 2005-02-28
US7700314B2 (en) 2010-04-20
EP1075281A2 (en) 2001-02-14
CA2330451A1 (en) 1999-11-04
EP1421956A1 (en) 2004-05-26
NO332224B1 (no) 2012-07-30
WO1999055377A9 (en) 2000-03-02
CN1637020A (zh) 2005-07-13
PL344490A1 (en) 2001-11-05
JP4574007B2 (ja) 2010-11-04
US20040043002A1 (en) 2004-03-04
KR20010071158A (ko) 2001-07-28
DE69936409T2 (de) 2008-04-17
CY1108022T1 (el) 2013-09-04
SI1421956T1 (sl) 2007-10-31
PL196533B1 (pl) 2008-01-31
DE69920002T2 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
CN100335503C (zh) 多元醇干扰素β偶联物
TWI364295B (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US5985263A (en) Substantially pure histidine-linked protein polymer conjugates
JP2007533665A (ja) 新規ｇ−ｃｓｆ結合体
WO2011041376A1 (en) Modified granulocyte colony stimulating factor (g-csf)
HK1076115B (en) Polyol-ifn-beta conjugates
HK1038194B (en) Polyol-ifn-beta conjugates
MXPA00010223A (en) Polyol-ifn-beta conjugates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1038194

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: SERONO LABORATORY CO., LTD.

Free format text: FORMER OWNER: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

Effective date: 20080516

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080516

Address after: Swiss Coyne Hince

Patentee after: Serono Lab

Address before: Curacao, Netherlands Antilles

Patentee before: Applied Research Systems ARS Holding N. V.

ASS Succession or assignment of patent right

Owner name: MERCK SERONO CO., LTD.

Free format text: FORMER OWNER: SERONO LABORATORIES LTD.

Effective date: 20100323

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: COINSINS, SWITZERLAND TO: SWITZERLAND COINSIMS

TR01 Transfer of patent right

Effective date of registration: 20100323

Address after: Switzerland Cohen Sins

Patentee after: Merck Serono S. A.

Address before: Swiss Coyne Hince

Patentee before: Serono Lab

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050202

Termination date: 20130428